ClinicalTrials.gg
Not yet recruitingNCT07345416Updated Jan 15, 2026

A Clinical Trial Assessing the Efficacy and Safety of ST-1 Silicone Hydrogel Daily Disposable Soft Contact Lenses Compared to Miru 1day UpSide

An interventional study of ST-1 and Miru 1day UpSide in Myopia, Soft Contact Lenses and Daily Disposable Soft Contact Lenses, sponsored by Menicon Co., Ltd.. Not yet recruiting at 6 sites in Taiwan. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Menicon Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Myopia with a site in Taiwan — 6 open to participants now, 8 under way, none of them phase 3. Myopia · Taiwan.

Planned enrollment
17th of 31
63 · median 65
Started
2026
with 1 other
No phase
23 of 40
5 open now
Registered
39th of 40
by date

Among the 40 studies in Myopia with a site in Taiwan, this one is the 17th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, and was the 39th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

6 of the 40 studies in Myopia with a site in Taiwan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Myopia with a site in Taiwan, or all of them as a file.
02

Study summary

This study will enroll 63 eligible subjects (126 eligible eyes, complete at least 108 evaluable eyes) in approximately 6 different medical centers in Taiwan, in order to evaluate the efficacy and safety of ST-1 silicone hydrogel daily disposable soft contact lenses (ST-1 lenses) compared to Miru 1day UpSide. Enrolled subjects will be randomized in a 2:1 test to control ratio at Visit 1. Each site will enroll 8 (intended minimum) to 12 (intended maximum) subjects. In order to eliminate the bias, the Investigators and the evaluators will be masked to the treatment assignment of the randomization code. During the study, the Investigator(s) will examine the ocular health via inquiry, slit lamp biomicroscopy (SLB), visual acuity (VA) test, keratometry, and refractive changes. The Investigator(s) will check ocular health and evaluate the inclusion/exclusion criteria of subjects at screening. After entering the study, subjects will be required to wear the lenses on a daily basis, record daily wearing time on a diary, return to the study site at scheduled visits for evaluations and complete the self-assessment questionnaire at Visit 2 to Visit 7 (1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months).

03

Conditions studied

  • Myopia
  • Soft Contact Lenses
  • Daily Disposable Soft Contact Lenses

Browse trials for

Keywords

  • Myopia
  • Soft Contact Lenses
  • Daily Disposable Soft Contact Lenses
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. With either gender aged between 18 to 40 (inclusive) years old.
  2. Diagnosis of myopia in both eyes, each ranging from -0.50D to 6.00D with manifest astigmatism of ≤ 1.00D per eye.
  3. Understands and signs an form (ICF).
  4. Willing to adhere to the instructions set forth in this study as well as understand and complete all specified evaluation.
  5. Willing and able to refrain from using any other contact lenses other than those provided for the duration of the study.
  6. Has experience and capability of wearing soft contact lenses.
  7. Be a habitual soft contact lenses wearer in both eyes, defined as wearing lenses for at least 8 hours per day, 5 days per week, for a minimum duration of 30 days.
  8. Tear breakup time (TBUT) > 5 seconds in each eye.

Exclusion criteria

Exclusion Criteria:

  1. Eyes with abnormality or disease as follows:

    1. Evidence of lid abnormality or infection (e.g., entropion, ectropion, chalazia, and recurrent styes).
    2. slit lamp findings (e.g., infiltrates or other slit lamp findings Level 2 or above: corneal edema, tarsal abnormalities, and conjunctival injection).
    3. Other active ocular disease (e.g., uveitis, corneal epithelial defect, severe dry eye, lacrimal duct defect, glaucoma, cornea [infiltrates], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology).
    4. History of recurrent corneal erosions.
    5. Aphakia.
  2. Ocular or systemic allergies or diseases that may interfere with contact lens wear, occur within 2 weeks prior to the Screening Visit.
  3. Use of topical ocular medications, except artificial tear, within 7 days prior to the Screening Visit.
  4. History of refractive, ocular, or intraocular surgery.
  5. Participation in any clinical trial (with the exception of retrospectives studies) within 30 days prior to the Screening Visit.
  6. Have risks in dangerous and significant eye edema, congestions, corneal abrasion or neovascularization when wearing contact lens.
  7. Any corneal surface roughness.
  8. Unable to achieve best corrected visual acuity (BCVA) of logMAR 0.1 or better in each eye at distance using manifest refraction.
  9. Females who are pregnant, breastfeeding or who intend to become pregnant over the course of the study.
  10. Current drug or alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirement.
  11. Allergy to any component in the study product.
  12. Subjects who wore monovision, multifocal, toric, or rigid contact lenses within 30 days prior to the Screening Visit.

    Note: Monovision is defined as a vision correction method for treating presbyopia in which the dominant eye is corrected for distance vision and the non-dominant eye is corrected for near vision.

  13. Use of systemic medications (e.g., chronic use) that are known to interfere with contact lenses wear at the Investigators discretion within 14 days prior to the Screening Visit.
  14. Other conditions not suitable for participating in this study judged by the Investigators.
  15. Live in dusty or pharmaceutical environments.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    ST-1

    Subjects will be randomized at Visit 1 with a 2:1 allocation ratio (approximately two-thirds assigned to this arm).

    Device: ST-1

  • Active comparator
    Miru 1day UpSide

    Subjects will be randomized at Visit 1 with a 2:1 allocation ratio (approximately one-third assigned to this arm).

    Device: Miru 1day UpSide

Interventions

  • DeviceST-1

    ST-1 lens worn in daily wear, daily disposable mode.

  • DeviceMiru 1day UpSide

    Miru 1day UpSide lens worn in daily wear, daily disposable mode.

06

What researchers measure

Primary outcomes

  1. Corrected distance Logarithm of the Minimum Angle of Resolution (logMAR) visual acuity at the final visit (Visit 7)

    Assessed using a Tumbling E Series ETDRS® chart.

    Time frame: Screening, 3 months following enrolment

Secondary outcomes

  1. Self-assessment of eye symptoms

    This questionnaire includes 11 items assessing symptoms during contact lens wear: discomfort, tearing, photophobia, itching, burning, halos, dryness, variable vision, blurred vision, pain, and other (specify if present). Scale: 0-4 (minimum = 0, maximum = 4), where higher scores indicate worse symptoms. Grades: 0 = None 1. = Trace 2. = Mild 3. = Moderate 4. = Severe

    Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment

  2. Self-assessment of lens performance

    This questionnaire includes 5 items assessing lens performance during contact lens wear: insertion comfort, overall comfort, vision, insertion handling, and removal handling. Scale: 0-5 (minimum = 0, maximum = 5), where higher scores indicate worse performance. Grades: 【comfort】 0 = Excellent 1 = Very comfortable 2 = Comfortable 3 = Slightly uncomfortable 4 = Very uncomfortable 5 = Causes pain 【vision】 0 = Excellent 1. = Very good 2. = Good 3. = Poor 4. = Very poor 5. = Unacceptable 【handling】 0 = Excellent 1. = Very good 2. = Good 3. = Poor 4. = Very poor 5. = Unmanageable

    Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment

  3. Total wearing hours

    Cumulative duration of lens wear throughout the study period, determined from the daily wearing time recorded by participants in the electronic patient-reported outcome (ePRO) diary.

    Time frame: Daily for 3 months after enrollment

  4. Total wearing days

    Total number of days the study lenses were worn for 8 hours or more, based on the daily wearing time entered by participants in the electronic patient-reported outcome (ePRO) diary. A wearing day is defined as a day with 8 hours or more of lens wear.

    Time frame: Daily for 3 months after enrollment

  5. Average wearing hour each time

    Average duration of lens wear for each individual application, derived from the wearing data entered by participants in the electronic patient-reported outcome (ePRO) diary.

    Time frame: Daily for 3 months after enrollment

  6. Daily wearing hour

    Average number of hours the study lenses were worn per day, as recorded by participants in the electronic patient-reported outcome (ePRO) diary.

    Time frame: Daily for 3 months after enrollment

  7. Corrected distance visual acuity (CDVA) change with the dispensed lenses from baseline

    Assessed using a Tumbling E Series ETDRS® chart.

    Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment

  8. Slit lamp biomicroscopy (SLB) findings

    Assessed using a slit lamp.

    Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment

  9. Change from baseline in keratometry readings

    To evaluate the absolute change from baseline in keratometry readings between Screening and the 3 months visit.

    Time frame: Screening, 3 months following enrolment

  10. Percent change from baseline in keratometry readings

    To evaluate the percent change from baseline in keratometry readings between Screening and the 3-month visit.

    Time frame: Screening, 3 months following enrolment

  11. Change from baseline in refractive parameters

    To evaluate the absolute change from baseline in refractive parameters, including sphere (S), cylinder (C), and axis (A), measured by subjective refraction test between Screening and the 3-month visit.

    Time frame: Screening, 3 months following enrolment

  12. Percent change from baseline in refractive parameters

    To evaluate the percent change from baseline in refractive parameters, including sphere (S), cylinder (C), and axis (A), measured by subjective refraction test between Screening and the 3-month visit.

    Time frame: Screening, 3 months following enrolment

  13. Adverse events

    AE will be evaluated by the investigator.

    Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment

  14. Lens fitting and surface assessment

    Lens fitting will be assessed with a slit lamp, and surface assessment will be assessed with a slit lamp or a stereomicroscope.

    Time frame: 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment

  15. Device deficiency

    A device deficiency refers to any inadequacy of the investigational product regarding identity, quality, durability, reliability, safety, or performance, including malfunctions, use errors, and labeling issues. Categories include: Failure to meet product specifications (e.g., incorrect lens power/diameter/base curve/color) Lens cloudy or surface/edge defect Torn lens during handling/in pack Packaging deficit (e.g., mislabeled product, tampered seal, leaking container) Suspect contamination Lack of performance (e.g., fit changes under hypobaric or low-humidity conditions) Other If such an event occurs, investigators must evaluate, record, and report all deficiencies and malfunctions during the trial using the device deficiency evaluation form. The frequency of device deficiencies will be summarized for safety evaluation and compared between treatments.

    Time frame: 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment

  16. Overall lens dicontinuation rate

    Permanent discontinuation of lens wear, if it occurs, will be recorded via ePRO. The overall discontinuation rate will be calculated and compared between treatments using Chi-square or Fisher's exact test.

    Time frame: Daily for 3 months after enrollment

  17. Lens discontinuation rate by reason

    Reasons for permanent discontinuation (e.g., discomfort, adverse event, convenience), if they occur, will be collected via ePRO, categorized, and tabulated by visit and overall.

    Time frame: Daily for 3 months after enrollment

  18. Lens replacement

    Lens replacement is defined as removal and reapplication of a lens, regardless of whether a new lens is used. If it occurs, all reasons (e.g., sleeping, rest, device deficiency, adverse events, other) will be recorded via ePRO and tabulated by visit and overall.

    Time frame: Daily for 3 months after enrollment

  19. Artificial tears usage frequency

    Participants will record their daily usage of artificial tears via ePRO, if applicable. The record will include both the frequency of use and the number of drops applied each time.

    Time frame: Daily for 3 months after enrollment

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 7 months is above that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 15, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07345416
Lead sponsor
Menicon Co., Ltd.
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion